What is the role of platinum agents in the treatment of metastatic breast cancer in patients with BRCA mutations?

The TNT study compared taxanes versus carboplatin in triple negative breast cancer and did not show a difference in response rate. However, amongst BRCA germline mutation carriers there was a significantly higher response rate amongst women with BRCA mutations. Therefore, platinums are good options ...

In patients with BRCA mutations, the TNT trial does show benefit/ I would consider these agents in patients with BRCA mutations.